216 related articles for article (PubMed ID: 2608162)
21. Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition.
Easwaramoorthy B; Pichika R; Collins D; Potkin SG; Leslie FM; Mukherjee J
Synapse; 2007 Jan; 61(1):29-36. PubMed ID: 17068780
[TBL] [Abstract][Full Text] [Related]
22. Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study.
Unni LK; Radcliffe J; Latham G; Sunderland T; Martinez R; Potter W; Becker RE
Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):373-6. PubMed ID: 7934317
[TBL] [Abstract][Full Text] [Related]
23. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex.
Messamore E; Warpman U; Ogane N; Giacobini E
Neuropharmacology; 1993 Aug; 32(8):745-50. PubMed ID: 8413838
[TBL] [Abstract][Full Text] [Related]
24. Effects of cholinesterase inhibitors on a two-component chained schedule performance in rats.
Liu WF
Neurotoxicol Teratol; 2000; 22(3):389-96. PubMed ID: 10840182
[TBL] [Abstract][Full Text] [Related]
25. Modulation of acetylcholine release by nicotinic receptors in the rat brain.
De Sarno P; Giacobini E
J Neurosci Res; 1989 Feb; 22(2):194-200. PubMed ID: 2709442
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of muscarinic- and 5-HT1B-mediated modulation of [3H]acetylcholine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts of septal origin.
Cassel JC; Jeltsch H; Neufang B; Lauth D; Szabo B; Jackisch R
Brain Res; 1995 Dec; 704(2):153-66. PubMed ID: 8788910
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
28. In vivo dose response relationship between physostigmine and cholinesterase activity in RBC and tissues of rats.
Somani SM; Dube SN
Life Sci; 1989; 44(25):1907-15. PubMed ID: 2739507
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effect of suberogorgin on acetylcholinesterase.
Peng WD; Xu SB; Peng X
Zhongguo Yao Li Xue Bao; 1996 Jul; 17(4):369-72. PubMed ID: 9812727
[TBL] [Abstract][Full Text] [Related]
30. Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo.
Cuadra G; Giacobini E
J Pharmacol Exp Ther; 1995 Oct; 275(1):228-36. PubMed ID: 7562554
[TBL] [Abstract][Full Text] [Related]
31. The relationship between oxime-induced reactivation of carbamylated acetylcholinesterase and antidotal efficacy against carbamate intoxication.
Harris LW; Talbot BG; Lennox WJ; Anderson DR
Toxicol Appl Pharmacol; 1989 Mar; 98(1):128-33. PubMed ID: 2494778
[TBL] [Abstract][Full Text] [Related]
32. Effects of T-82, a new quinoline derivative, on cholinesterase activity and extracellular acetylcholine concentration in rat brain.
Isoma K; Ishikawa M; Ohta M; Ogawa Y; Hasegawa H; Kohda T; Kamei J
Jpn J Pharmacol; 2002 Feb; 88(2):206-12. PubMed ID: 11928722
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration.
Somani SM
Biopharm Drug Dispos; 1989; 10(2):187-203. PubMed ID: 2706318
[TBL] [Abstract][Full Text] [Related]
34. Acetylcholinesterase inhibition by (+)physostigmine and efficacy against lethality induced by soman.
Harris LW; Anderson DR; Pastelak AM; Vanderpool B
Drug Chem Toxicol; 1990; 13(2-3):241-8. PubMed ID: 2276342
[TBL] [Abstract][Full Text] [Related]
35. Side effects of physostigmine as a pretreatment in guinea pigs.
Philippens IH; Wolthuis OL; Busker RW; Langenberg JP; Melchers BP
Pharmacol Biochem Behav; 1996 Sep; 55(1):99-105. PubMed ID: 8870044
[TBL] [Abstract][Full Text] [Related]
36. Surgery-induced changes in rat IL-1β and acetylcholine metabolism: role of physostigmine.
Plaschke K; Müller AK; Kopitz J
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):663-70. PubMed ID: 24890001
[TBL] [Abstract][Full Text] [Related]
37. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.
Cerbai F; Giovannini MG; Melani C; Enz A; Pepeu G
Eur J Pharmacol; 2007 Oct; 572(2-3):142-50. PubMed ID: 17643410
[TBL] [Abstract][Full Text] [Related]
38. Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
Psychopharmacology (Berl); 1993; 112(4):415-20. PubMed ID: 7871051
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cholinesterase-associated aryl acylamidase activity by anticholinesterase agents: focus on drugs potentially effective in Alzheimer's disease.
Costagli C; Galli A
Biochem Pharmacol; 1998 May; 55(10):1733-7. PubMed ID: 9634011
[TBL] [Abstract][Full Text] [Related]
40. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Kamal MA; Al-Jafari AA; Yu QS; Greig NH
Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
